HLA Class II Alleles DRB1*11:01 and DBQ1*03:01 Unmask Immunogenic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab by Elena Iemma | May 21, 2026
Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products by Elena Iemma | Dec 8, 2025
Immunogenicity risk assessment of synthetic peptide drugs and their impurities by Elena Iemma | Jul 27, 2023Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
